Review
Oncology
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
Summary: Recurrence of hepatocellular carcinoma after liver transplantation is a major concern, with poor prognosis and uncertainty in management. There is currently lack of specific surveillance strategy and sufficient data to support immunosuppressive drugs and adjuvant therapy.
Article
Oncology
Zhongyi Jiang, Qianwei Jiang, Xu Fang, Pusen Wang, Weitao Que, Hao Li, Yang Yu, Xueni Liu, Chunguang Wang, Lin Zhong
Summary: The recipient C7 rs9292795 gene polymorphism is associated with HCC recurrence after orthotopic liver transplantation, serving as a potential prognostic marker for HCC patients undergoing OLT.
Review
Radiology, Nuclear Medicine & Medical Imaging
Giuseppe Mamone, Settimo Caruso, Mariapina Milazzo, Giorgia Porrello, Ambra Di Piazza, Giovanni Gentile, Vincenzo Carollo, Francesca Crino, Gianluca Marrone, Gianvincenzo Sparacia, Luigi Maruzzelli, Roberto Miraglia, Salvatore Gruttadauria
Summary: Liver transplantation provides the best survival benefit for hepatocellular carcinoma (HCC) patients who cannot undergo resection. The Milan criteria have been developed to select suitable candidates for transplantation, aiming to improve survival and reduce the risk of HCC recurrence. However, up to 20% of cases experience HCC recurrence after transplantation, posing a significant challenge due to poor prognosis. Various extended criteria have been proposed to accommodate the increasing demand for organs and the associated higher risk of recurrence. Radiologists need to be aware of the possibility of HCC recurrence involving multiple organs after transplantation. Understanding the location and radiologic appearance of recurrent HCC is crucial for choosing the most appropriate therapy.
INSIGHTS INTO IMAGING
(2023)
Article
Gastroenterology & Hepatology
Kevin Tak-Pan Ng, Jiang Liu, Oscar Wai-Ho Yeung, Li Pang, Hoi Chung Shiu, Hui Liu, Xin Xiang Yang, Albert Chi-Yan Chan, Tiffany Cho-Lam Wong, Chung Mau Lo, Kwan Man
Summary: This study found that post-transplant cytokines CCL11, IFN alpha 2, and IL17A are significant predictors of tumor recurrence and survival after liver transplantation for hepatocellular carcinoma. A prediction model including these cytokines, the UCSF criteria, and pre-transplant AFP accurately predicted post-transplant tumor recurrence and guided refinements in surveillance and therapeutic strategies.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Su Jong Yu, Jeong-Ju Yoo, Dong Ho Lee, Su Jin Kim, Eun Ju Cho, Se Hyung Kim, Jeong-Hoon Lee, Yoon Jun Kim, Jeong Min Lee, Jae Young Lee, Jung-Hwan Yoon
Summary: Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced MRI can detect early stages of hepatocellular carcinoma (HCC) in patients with cirrhosis, but its survival benefit is unknown. This retrospective cohort study found that intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI improved the clinical outcomes of cirrhosis patients, including overall survival and time to progression.
Article
Nutrition & Dietetics
Xuan-vinh Kevin Nguyen, Jason Zhang, Ken Lee Chin, Stephen Bloom, Amanda J. Nicoll
Summary: This study compared the characteristics and survival rates of NAFLD-HCC patients to non-NAFLD-HCC patients, finding that NAFLD-HCC patients were more likely to be diagnosed based on symptoms and at an older age, with lower survival rates.
Article
Chemistry, Multidisciplinary
Han Jiang, Hao Fu, Tao Min, Ping Hu, Jianlin Shi
Summary: This study proposes a mild magnetocaloric regulation approach using a magnetogenetic nanoplatform (MPFD) to promote the proliferation and activation of tumor-infiltrating NK cells in liver cancer immunotherapy. The magnetothermally responsive MPFD serves as a magnetism-heat nanotransducer to induce the gene transcription of IL-2 cytokine in orthotopic liver tumor for NK cell proliferation and activation.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2023)
Article
Medicine, General & Internal
Indah Jamtani, Kwang-Woong Lee, Yunhee Choi, YoungRok Choi, Jeong-Moo Lee, Eui-Soo Han, Kwangpyo Hong, Gyu-Seong Choi, Jong Man Kim, Nam-Joon Yi, Suk Kyun Hong, Jeik Byun, Su Young Hong, Sanggyeun Suh, Jae-Won Joh, Kyung-Suk Suh
Summary: This study aimed to develop a tailored prediction model of HCC-specific survival after transplantation, validated internally and externally. By combining multiple risk factors, the model showed good accuracy in predicting HCC-specific survival tailored for patients undergoing transplantation. The calculated SALT predictor provided accurate information on expected survival rates based on risk scores and specific characteristics.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Mun Chae Choi, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Deok-Gie Kim
Summary: This study investigated the use of antiplatelet drugs in preventing hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). The findings suggest that antiplatelet therapy does not impact HCC recurrence or HCC-specific mortality when used after LT.
Article
Engineering, Biomedical
Tiancheng He, Joy Nolte Fong, Linda W. Moore, Chika F. Ezeana, David Victor, Mukul Divatia, Matthew Vasquez, R. Mark Ghobrial, Stephen T. C. Wong
Summary: This study developed a convergent artificial intelligence model to assess the risk of liver transplantation for hepatocellular carcinoma patients more objectively and expand the transplantation option to patients with the highest tumor burden.
COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
(2021)
Review
Biochemistry & Molecular Biology
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, Justin P. Canakis, Mohammad Bourmaf, Cyrus Adams-Mardi, Ameer Abutaleb, Lopa Mishra, Kirti Shetty
Summary: The emerging field of immuno-oncology has brought exciting developments in the treatment of hepatocellular carcinoma (HCC), with potential benefits in liver transplantation settings. Immune therapeutic agents have shown promise in down-staging advanced HCCs pre-transplant and managing recurrent HCC post-transplant. This review discusses optimal regimens in the context of liver transplantation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Tomomi Kogiso, Katsutoshi Tokushige
Summary: The incidence of NAFLD-related HCC is increasing, emphasizing the need for effective screening. Revised guidelines in Japan propose new management and surveillance strategies for NAFLD/NASH. Advanced fibrosis and lifestyle-related diseases are associated with HCC development.
Article
Gastroenterology & Hepatology
Ming Chao Tsai, Chee-Chien Yong, Chih-Che Lin, Wei-Chen Lee, Chih-Chi Wang, Chao-Hung Hung, I-Hsuan Chen, Yu-Fan Cheng, Chang-Chun Hsiao, Tsung-Hui Hu, Chao-Long Chen
Summary: The study found that LDLT may be a valuable therapeutic option for selected patients with BCLC stage B HCC, as patients treated with LDLT achieved better overall survival compared to the non-LDLT group. Age, NLR, and LRT before LDLT were identified as independent risk factors for HCC recurrence and overall survival.
HEPATOBILIARY SURGERY AND NUTRITION
(2021)
Review
Gastroenterology & Hepatology
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Summary: The incidence of hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD) is increasing globally, including Asia. Compared to virus-related HCC, most patients with NAFLD-related HCC are diagnosed at a late stage and older age due to lack of HCC surveillance. This review provides an overview of the mechanism of hepatocarcinogenesis in NAFLD, preventive strategies for NAFLD-related HCC, and surveillance strategies for patients with NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Romain Donne, Amaia Lujambio
Summary: The liver is a common site for primary cancer and a major cause of cancer death. Hepatocellular carcinoma (HCC) accounts for the majority of liver cancers. Immune-checkpoint inhibitors have shown promise in the treatment of HCC, but further understanding of the tumor microenvironment and the development of additional biomarkers are needed. Other immune-targeting strategies are also being developed. This review provides an overview of the HCC immune microenvironment and current immunotherapies.